Logo

GSK Tests out Ambit s Profiling Technology

Mar 04, 2003

NEW YORK, March 4 - GlaxoSmithKline is evaluating Ambit Biosciences' screening technology to characterize small molecule kinase inhibitors, Ambit said today.

 

Since January, Ambit has been studying interactions between GSK's kinase inhibitors and proteins using its phage display-based screening approach.

 

Ambit Biosciences is based in San Diego.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.